Oral non-peptide ghrelin receptor agonist. Sustained GH and IGF-1 elevation through 24-hour pharmacokinetics.
Merck-developed small molecule (not a peptide — included because it's ubiquitous in stacks). Phase 2 trials in elderly fall-prevention failed primary endpoint despite biomarker improvement. Sustained 24-hour GH/IGF-1 elevation distinguishes it from injectable GHRPs but raises concerns about loss of pulsatility.
Not a peptide; not approved. Non-pulsatile GH/IGF-1 elevation is mechanistically distinct from injectable secretagogues — long-term effects on insulin sensitivity and cancer risk are debated.
Stack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
Daily oral dosing raises GH and IGF-1 modestly over months. Long-term studies show real lean-mass and bone-density effects but also documented insulin-resistance signal and edema. Discontinued by Merck for development despite trial data.
Popular for sleep depth, appetite increase, and lean-mass support during caloric surplus. Universal complaint: ankle/wrist water retention. Polarized on whether the insulin-resistance signal is meaningful for non-diabetic users at moderate doses.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Dosing assumption: 10-25 mg daily oral
MK-677 was not FDA-approved despite long clinical trial history (Merck discontinued development). Currently grey-market only. PCAC review scheduled February 2027 may change access.
As of 2026-04Public-source attribution across the production + distribution chain. Stack does not endorse vendors — this is who is in the chain, not which one is best.
One of the most consistently recommended vendors on r/Peptides since the Peptide Sciences shutdown (March 2026). Third-party COA published per batch. HPLC purity ≥99%.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Long-established US vendor (7+ years). Broad catalog including GHRPs, GHRHs, and cognitive peptides. Third-party HPLC and mass-spec COA per batch. Active Finnrick Analytics coverage.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Newer vendor with fast turnaround and competitive pricing. Third-party COA on all products. Building Finnrick coverage. Frequently recommended post-Peptide Sciences shutdown.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Established vendor with multi-year community track record. Offers peptide blends (Wolverine Stack, etc.) alongside singles. Third-party COA available on request.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Known for above-average catalog depth, including harder-to-find compounds (SS-31, humanin, Foxo4-DRI). Third-party HPLC published. Active Finnrick coverage.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Clean storefront, competitive pricing, strong community mentions. Third-party COA on most products. Ships to US with fast turnaround.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Tampa-based telehealth clinic specializing in hormone and peptide therapy. Prescribing provider + compounding pharmacy fulfillment. BPC-157, CJC/Ipa, Ipamorelin, PT-141, Sermorelin. Prescription required.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
FDA Cat. 2 removed Apr 2026 — PCAC review Feb 2027
FDA's Pharmacy Compounding Advisory Committee scheduled to review the second cohort of peptides removed from Category 2 in April 2026. Panel votes whether to add each to the official 503A bulks list.
FDA published a Federal Register notice on April 15 2026 removing 12 peptides from the Category 2 ('significant safety concerns') compounding list, paving the way for PCAC review for inclusion on the 503A bulks list. Peptides removed: BPC-157, TB-500, Epitalon, GHK-Cu (injectable), MOTS-c, DSIP, Dihexa Acetate, MK-677, Melanotan II, KPV, Semax, LL-37.
FDA's Pharmacy Compounding Advisory Committee categorized a wide list of peptides as Category 2 ('significant safety concerns'), effectively banning their compounding at 503A and 503B pharmacies. Affected: BPC-157, TB-500, Epitalon, GHK-Cu, MOTS-c, DSIP, Dihexa, MK-677, Melanotan II, KPV, Semax, Selank, LL-37 and others.